Aspen Pharmacare annual normalised earnings rise 22% on Mounjaro demand
Aspen Pharmacare (APN) reported annual normalised earnings up 22%, citing strong demand for obesity and diabetes treatment Mounjaro it distributes and improving profitability in its manufacturing business.
By Nqobile Dludla South Africa's Aspen Pharmacare JSE:APN reported a 22% rise in annual normalised earnings on Wednesday, supported by strong demand for obesity and diabetes treatment Mounjaro, which it distributes, and improving profitability in its manufacturing business. The drugmaker said normalised…